Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.
Products, services, technology
- Privosegtor, a neuroprotective candidate in registrational trials for the treatment of optic neuropathies (ON and NAION);
- OCS-01, an eye drop in registrational trials for DME;
- Licaminlimab, a novel topical anti-TNFα in registrational trial to drive precision medicine in DED.
Cooperation possibilities
Oculis is open to collaboration. For information or proposals, please use one of the following email addresses:
- http://www.oculis.com
- +41 41 711 39 60
- Send an email
- Louie-Anne Gauthier
Some insights
- Healthcare professionals
- Investors
- Strategics
- Talents
- Patients associations
By redefining how we understand complex diseases and with a relentless focus on highly differentiated development opportunities, we aim to transform treatment approaches in neuro-ophthalmology and bring a lasting impact to the lives of patients.
At the heart of our visionary innovation is a bold commitment to rethink what's possible for patients. Guided by unmet medical needs and grounded in cutting-edge science, we are in pursuit of health breakthroughs that go beyond incremental changes and challenge conventions.
Prof. Ramin Tadayoni was a highly accomplished world renowned retina specialist, truly a luminary in the field of ophthalmology. In addition to scientific accomplishments, he is remembered for his kindness, mentorship and unwavering commitment to advancing the field and bettering patients' lives.
Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. Its team is composed of experts in the field of R&D. drug development, regulatory affairs, CMC, quality, finance, HR, commercialization and general management.
Oculis is a global biopharmaceutical company focused on innovation addressing neuro-ophthalmic and ophthalmic conditions with significant unmet medical needs. It aim is to transform treatment approaches and bring a lasting impact to the lives of patients.
The Swiss Biotech Association can play a key role in representing the interests of the Swiss Biotech industry. It can support its members by securing favorable framework conditions, facilitating access to talents and financial resources while enhancing visibility of promising biotech companies.
Oculis is pen to get in contact with the following groups of individuals in our field of interest:
